Serum resistin is positively correlated with the accumulation of metabolic syndrome factors in type 2 diabetes

Clinical Endocrinology

Volumn 69, Issue 1, 2008, Pages 74-80

  Osawa, Haruhiko ^a   Ochi, Masaaki ^a   Tabara, Yasuharu ^a   Kato, Kenichi ^b   Yamauchi, Junko ^a   Takata, Yasunori ^a   Nishida, Wataru ^a   Onuma, Hiroshi ^a   Shimizu, Ikki ^b   Fujii, Yasuhisa ^b   Miki, Tetsuro ^a   Ohashi, Jun ^c   Makino, Hideichi ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Ehime Prefectural Hospital   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; C REACTIVE PROTEIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; RESISTIN; TRIACYLGLYCEROL;

ADULT; AGE; ARTICLE; ATHEROSCLEROSIS; BLOOD CHEMISTRY; BODY MASS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENDER; GENE ACTIVITY; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; HYPERTENSION; JAPANESE; LIPOPROTEIN BLOOD LEVEL; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTIPLE REGRESSION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; REGRESSION ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ATHEROSCLEROSIS; DIABETES MELLITUS, TYPE 2; DISEASE SUSCEPTIBILITY; FEMALE; HUMANS; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; RESISTIN; RISK FACTORS;

EID: 45349103353     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2007.03154.x     Document Type: Article

References (48)

1. Steppan, C. Lazar, M. (2004) The current biology of resistin. Journal of Internal Medicine, 255, 439 447.
2. Steppan, C.M., Bailey, S.T., Bhat, S., Brown, E.J., Banerjee, R.R., Wright, C.M., Patel, H.R., Ahima, R.S. Lazar, M.A. (2001) The hormone resistin links obesity to diabetes. Nature, 409, 307 312.
3. Banerjee, R.R., Rangwala, S.M., Shapiro, J.S., Rich, A.S., Rhoades, B., Qi, Y., Wang, J., Rajala, M.W., Pocai, A., Scherer, P.E., Steppan, C.M., Ahima, R.S., Obici, S., Rossetti, L. Lazar, M.A. (2004) Regulation of fasted blood glucose by resistin. Science, 303, 1195 1198.
4. Rangwala, S.M., Rich, A.S., Rhoades, B., Shapiro, J.S., Obici, S., Rossetti, L. Lazar, M.A. (2004) Abnormal glucose homeostasis due to chronic hyperresistinemia. Diabetes, 53, 1937 1941.
5. DeFronzo, R.A., Bonadonna, R.C. Ferrannini, E. (1992) Pathogenesis of NIDDM. A balanced overview. Diabetes Care, 15, 318 368.
6. Osawa, H., Onuma, H., Murakami, A., Ochi, M., Nishimiya, T., Kato, K., Shimizu, I., Fujii, Y., Ohashi, J. Makino, H. (2002) Systematic search for single nucleotide polymorphisms in the resistin gene: the absence of evidence for the association of three identified single nucleotide polymorphisms with Japanese type 2 diabetes. Diabetes, 51, 863 866.
7. Osawa, H., Yamada, K., Onuma, H., Murakami, A., Ochi, M., Kawata, H., Nishimiya, T., Niiya, T., Shimizu, I., Nishida, W., Hashiramoto, M., Kanatsuka, A., Fujii, Y., Ohashi, J. Makino, H. (2004) The G/G genotype of a resistin single-nucleotide polymorphism at -420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3. American Journal of Human Genetics, 75, 678 686.
8. Osawa, H., Onuma, H., Ochi, M., Murakami, A., Yamauchi, J., Takasuka, T., Tanabe, F., Shimizu, I., Kato, K., Nishida, W., Yamada, K., Tabara, Y., Yasukawa, M., Fujii, Y., Ohashi, J., Miki, T. Makino, H. (2005) Resistin SNP-420 determines its monocyte mRNA and serum levels inducing type 2 diabetes. Biochemical and Biophysical Research Communications, 335, 596 602.
9. Osawa, H., Tabara, Y., Kawamoto, R., Ohashi, J., Ochi, M., Onuma, H., Nishida, W., Yamada, K., Nakura, J., Kohara, K., Miki, T. Makino, H. (2007) Plasma resistin, associated with single nucleotide polymorphism -420, is correlated with insulin resistance, lower HDL cholesterol, and high-sensitivity C-reactive protein in the Japanese general population. Diabetes Care, 30, 1501 1506.
10. Tokuyama, Y., Osawa, H., Ishizuka, T., Onuma, H., Matsui, K., Egashira, T., Makino, H. Kanatsuka, A. (2007) Serum resistin level is associated with insulin sensitivity in Japanese type 2 diabetes. Metabolism, 56, 693 698.
11. Xu, J.Y., Sham, P.C., Xu, A., Tso, A.W.K., Wat, N.M.S., Cheng, K.Y., Fong, C.H.Y., Janus, E.D. Lam, K.S.L. (2007) Resistin gene polymorphisms and progression of glycaemia in southern Chinese: a 5-year prospective study. Clinical Endocrinology, 66, 211 217.
12. Eckel, R.H., Grundy, S.M. Zimmet, P.Z. (2005) The metabolic syndrome. Lancet, 365, 1415 1428.
13. Chen, C.C., Li, T.C., Li, C.I., Liu, C.S., Wang, H.J. Lin, C.C. (2005) Serum resistin level among healthy subjects: relationship to anthropometric and metabolic parameters. Metabolism, 54, 471 475.
14. Shetty, G.K., Economides, P.A., Horton, E.S., Mantzoros, C.S. Veves, A. (2004) Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care, 27, 2450 2457.
15. Utzschneider, K.M., Carr, D.B., Tong, J., Wallace, T.M., Hull, R.L., Zraika, S., Xiao, Q., Mistry, J.S., Retzlaff, B.M., Knopp, R.H. Kahn, S.E. (2005) Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans. Diabetologia, 48, 2330 2333.
16. The Expert Committee on the Diagnosis Classification of Diabetes Mellitus (2003) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care, 26 (Suppl. 1 S5 S20.
17. Expert Panel on Detection, Evaluation, Treatment of High Blood Cholesterol in Adults (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA, 285, 2486 2497.
18. The Examination Committee of Criteria for 'Obesity Disease' in Japan, Japan Society for the Study of Obesity (2002) New criteria for 'obesity disease' in Japan. Circulation Journal, 66, 987 992.
19. Arita, Y., Kihara, S., Ouchi, N., Takahashi, M., Maeda, K., Miyagawa, J., Hotta, K., Shimomura, I., Nakamura, T., Miyaoka, K., Kuriyama, H., Nishida, M., Yamashita, S., Okubo, K., Matsubara, K., Muraguchi. M., Ohmoto, Y., Funahashi, T. Matsuzawa, Y. (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochemical and Biophysical Research Communications, 257, 79 83.
20. Axelsson, J., Bergsten, A., Qureshi, A.R., Heimburger, O., Barany, P., Lonnqvist, F., Lindholm, B., Nordfors, L., Alvestrand, A. Stenvinkel, P. (2006) Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney International, 69, 596 604.
21. Azuma, K., Katsukawa, F., Oguchi, S., Murata, M., Yamazaki, H., Shimada, A. Saruta, T. (2003) Correlation between serum resistin level and adiposity in obese individuals. Obesity Research, 11, 997 1001.
22. Degawa-Yamauchi, M., Bovenkerk, J.E., Juliar, B.E., Watson, W., Kerr, K., Jones, R., Zhu, Q. Considine, R.V. (2003) Serum resistin (FIZZ3) protein is increased in obese humans. Journal of Clinical Endocrinology and Metabolism, 88, 5452 5455.
23. Jung, H.S., Youn, B.S., Cho, Y.M., Yu, K.Y., Park, H.J., Shin, C.S., Kim, S., Lee, H. Park, K. (2005) The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus. Metabolism, 54, 314 320.
24. Kadowaki, T. Yamauchi, T. (2005) Adiponectin and adiponectin receptors. Endocrine Reviews, 26, 439 451.
25. Ryo, M., Nakamura, T., Kihara, S., Kumada, M., Shibazaki, S., Takahashi, M., Nagai, M., Matsuzawa, Y. Funahashi, T. (2004) Adiponectin as a biomarker of the metabolic syndrome. Circulation Journal, 68, 975 981.
26. Cho, Y.M., Youn, B.-S., Chung, S.S., Kim, K.W., Lee, H.K., Yu, K.-Y., Park, H.J., Shin, H.D. Park, K.S. (2004) Common genetic polymorphisms in the promoter of resistin gene are major determinants of plasma resistin concentrations in humans. Diabetologia, 47, 559 565.
27. Fujinami, A., Obayashi, H., Ohta, K., Ichimura, T., Nishimura, M., Matsui, H., Kawahara, Y., Yamazaki, M., Ogata, M., Hasegawa, G., Nakamura, N., Yoshikawa, T., Nakano, K. Ohta, M. (2004) Enzyme-linked immunosorbent assay for circulating human resistin: resistin concentrations in normal subjects and patients with type 2 diabetes. Clinica Chimica Acta, 339, 57 63.
28. Lee, J.H., Chan, J.L., Yiannakouris, N., Kontogianni, M., Estrada, E., Seip, R., Orlova, C. Mantzoros, C.S. (2003) Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. Journal of Clinical Endocrinology and Metabolism, 88, 4848 4856.
29. McTernan, P.G., Fisher, F.M., Valsamakis, G., Chetty, R., Harte, A., McTernan, C.L., Clark, P.M.S., Smith, S.A., Barnett, A.H. Kumar, S. (2003) Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. Journal of Clinical Endocrinology and Metabolism, 88, 6098 6106.
30. Youn, B.-S., Yu, K.-Y., Park, H.J., Lee, N.S., Min, S.S., Youn, M.Y., Cho, Y.M., Park, Y.J., Kim, S.Y., Lee, H.K. Park, K.S. (2004) Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism, 89, 150 156.
31. Nagaev, I. Smith, U. (2001) Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochemical and Biophysical Research Communications, 285, 561 564.
32. Patel, L., Buckels, A.C., Kinghorn, I.J., Murdock, P.R., Holbrook, J.D., Plumpton, C., Macphee, C.H. Smith, S.A. (2003) Resistin is expressed in human macrophages and directly regulated by PPARγ activators. Biochemical and Biophysical Research Communications, 300, 472 476.
33. Savage, D.B., Sewter, C.P., Klenk, E.S., Segal, D.G., Vidal-Puig, A., Considine R.V. O'Rahilly, S. (2001) Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-γ action in humans. Diabetes, 50, 2199 2202.
34. Weisberg, S., McCann, D., Desai, M., Rosenbaum, M., Leibel, R. Ferrante, A.J. (2003) Obesity is associated with macrophage accumulation in adipose tissue. Journal of Clinical Investigation, 112, 1796 1808.
35. Xu, H., Barnes, G.T., Yang, Q., Tan, G., Yang, D., Chou, C.J., Sole, J., Nichols, A., Ross, J.S., Tartaglia, L.A. Chen, H. (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. Journal of Clinical Investigation, 112, 1821 1830.
36. Sato, N., Kobayashi, K., Inoguchi, T., Sonoda, N., Imamura, M., Sekiguchi, N., Nakashima, N. Nawata, H. (2005) Adenovirus-mediated high expression of resistin causes dyslipidemia in mice. Endocrinology, 146, 273 279.
37. Furuhashi, M., Ura, N., Higashiura, K., Murakami, H. Shimamoto, K. (2003) Circulating resistin levels in essential hypertension. Clinical Endocrinology, 59, 507 510.
38. Kawanami, D., Maemura, K., Takeda, N., Harada, T., Nojiri, T., Imai, Y., Manabe, I., Utsunomiya, K. Nagai, R. (2004) Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochemical and Biophysical Research Communications, 314, 415 419.
39. Verma, S., Li, S.H., Wang, C.H., Fedak, P.W., Li, R.K., Weisel, R.D. Mickle, D.A. (2003) Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation, 108, 736 740.
40. Calabro, P., Samudio, I., Willerson, J.T. Yeh, E.T. (2004) Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation, 110, 3335 3340.
41. Norata, G.D., Ongari, M., Garlaschelli, K., Raselli, S., Grigore, L. Catapano, A.L. (2007) Plasma resistin levels correlate with determinants of the metabolic syndrome. European Journal of Endocrinology, 156, 279 284.
42. Kunnari, A., Ukkola, O. Kesaniemi, Y.A. (2005) Resistin polymorphisms are associated with cerebrovascular disease in Finnish type 2 diabetic patients. Diabetic Medicine, 22, 583 589.
43. Menzaghi, C., Coco, A., Salvemini, L., Thompson, R., De Cosmo, S., Doria, A. Trischitta, V. (2006) Heritability of serum resistin and its genetic correlation with insulin resistance-related features in nondiabetic Caucasians. Journal of Clinical Endocrinology and Metabolism, 91, 2792 2795.
44. Derosa, G., Fogari, E., D'Angelo, A., Cicero, A.F.G., Salvadeo, S.A.T., Ragonesi, P.D., Ferrari, I., Gravina, A., Fassi, R. Fogari, R. (2007) Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. Journal of Clinical Pharmacy and Therapeutics, 32, 261 268.
45. Anderlova, K., Dolezalova, R., Housova, J., Bosanska, L., Haluzikova, D., Kremen, J., Skrha, J. Haluzík, M. (2007) The influence of PPAR-α agonist fenofibrate on insulin sensitivity and selected adipose tissue-derived hormones in obese women with type 2 diabetes. Physiological Research, 56, 579 586.
46. Chu, C.S., Lee, K.T., Lee, M.Y., Su, H.M., Voon, W.C., Sheu, S.H. Lai, W.T. (2006) Effects of atorvastatin and atorvastatin withdrawal on soluble CD40L and adipocytokines in patients with hypercholesterolaemia. Acta Cardiologica, 61, 263 269.
47. Otto, C., Otto, B., Frost, R.J.A., Vogeser, M., Pfeiffer, A.F.H., Spranger, J. Parhofer, K.G. (2007) Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia. Acta Diabetologica, 44, 65 68.
48. Yin, W.H., Jen, H.L., Chen, J.W., Lin, S.J. Young, M.S. (2006) Differential effects of peroxisome proliferator-activated receptor ligands and sulfonylurea plus statin treatment on plasma concentrations of adipokines in type 2 diabetes with dyslipidemia. Diabetes and Metabolism, 32, 229 235.